Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
Indivior (NASDAQ/LSE: INDV) has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of biopharmaceutical industry experience and will oversee Corporate Communications, Government Affairs, Policy and Advocacy.
Prior to joining Indivior, Procter served as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led the successful launch of ZURZUVAE鈩�. She previously held leadership positions at Alexion Pharmaceuticals and MedImmune, and worked as a health policy advisor in the U.S. House of Representatives.
Indivior (NASDAQ/LSE: INDV) ha nominato Vanessa Procter Vicepresidente Esecutiva delle Relazioni Aziendali, a partire dal 7 luglio 2025. Procter vanta 25 anni di esperienza nel settore biofarmaceutico e sar脿 responsabile delle Comunicazioni Aziendali, Affari Governativi, Politiche e Advocacy.
Prima di entrare in Indivior, Procter 猫 stata Vicepresidente Senior delle Relazioni Aziendali presso Sage Therapeutics, dove ha guidato il lancio di successo di ZURZUVAE鈩�. In precedenza ha ricoperto ruoli di leadership presso Alexion Pharmaceuticals e MedImmune, lavorando inoltre come consulente per le politiche sanitarie alla Camera dei Rappresentanti degli Stati Uniti.
Indivior (NASDAQ/LSE: INDV) ha designado a Vanessa Procter como Vicepresidenta Ejecutiva de Asuntos Corporativos, con efecto a partir del 7 de julio de 2025. Procter aporta 25 a帽os de experiencia en la industria biofarmac茅utica y supervisar谩 las Comunicaciones Corporativas, Asuntos Gubernamentales, Pol铆ticas y Defensa.
Antes de unirse a Indivior, Procter fue Vicepresidenta Senior de Asuntos Corporativos en Sage Therapeutics, donde lider贸 el exitoso lanzamiento de ZURZUVAE鈩�. Anteriormente ocup贸 cargos directivos en Alexion Pharmaceuticals y MedImmune, y trabaj贸 como asesora de pol铆ticas de salud en la C谩mara de Representantes de los Estados Unidos.
Indivior (NASDAQ/LSE: INDV)電� 2025雲� 7鞗� 7鞚茧秬搿� Vanessa Procter毳� 旮办梾 鞐呺 雼措嫻 靾橃劃 攵靷灔鞙茧 鞛勲獏頄堨姷雼堧嫟. Procter電� 25雲勱皠鞚� 氚旍澊鞓れ牅鞎� 靷办梾 瓴诫牓鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 旮办梾 旎る雼堨紑鞚挫厴, 鞝曤秬 鞐呺, 鞝曥眳 氚� 鞓鬼樃 頇滊彊鞚� 齑濌磩頃� 鞓堨爼鞛呺媹雼�.
Indivior鞐� 頃╇頃橁赴 鞝�, Procter電� Sage Therapeutics鞐愳劀 旮办梾 鞐呺 靾橃劃 攵靷灔鞙茧 鞛頃橂┌ ZURZUVAE鈩㈧潣 靹标车鞝侅澑 於滌嫓毳� 鞚措亴鞐堨姷雼堧嫟. 鞚挫爠鞐愲姅 Alexion Pharmaceuticals鞕 MedImmune鞐愳劀 毽崝鞁� 鞐暊鞚� 靾橅枆頄堨溂氅�, 氙戈淡 頃橃洂鞐愳劀 氤搓贝 鞝曥眳 瓿犽鞙茧 鞚柬暅 瓴诫牓鞚� 鞛堨姷雼堧嫟.
Indivior (NASDAQ/LSE : INDV) a nomm茅 Vanessa Procter au poste de Vice-Pr茅sidente Ex茅cutive des Affaires Corporatives, 脿 compter du 7 juillet 2025. Procter apporte 25 ans d'exp茅rience dans l'industrie biopharmaceutique et supervisera les Communications Corporatives, les Affaires Gouvernementales, les Politiques et le Plaidoyer.
Avant de rejoindre Indivior, Procter 茅tait Vice-Pr茅sidente Senior des Affaires Corporatives chez Sage Therapeutics, o霉 elle a dirig茅 le lancement r茅ussi de ZURZUVAE鈩�. Elle a auparavant occup茅 des postes de direction chez Alexion Pharmaceuticals et MedImmune, et a travaill茅 comme conseill猫re en politique de sant茅 脿 la Chambre des repr茅sentants des 脡tats-Unis.
Indivior (NASDAQ/LSE: INDV) hat Vanessa Procter zum Executive Vice President f眉r Unternehmensangelegenheiten ernannt, mit Wirkung zum 7. Juli 2025. Procter bringt 25 Jahre Erfahrung in der biopharmazeutischen Industrie mit und wird die Bereiche Unternehmenskommunikation, Regierungsangelegenheiten, Politik und Interessenvertretung leiten.
Vor ihrem Eintritt bei Indivior war Procter Senior Vice President f眉r Unternehmensangelegenheiten bei Sage Therapeutics, wo sie den erfolgreichen Launch von ZURZUVAE鈩� leitete. Zuvor hatte sie F眉hrungspositionen bei Alexion Pharmaceuticals und MedImmune inne und arbeitete als Gesundheitspolitikberaterin im US-Repr盲sentantenhaus.
- None.
- None.
"We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to priorities and executing successful multi-stakeholder strategies that drive patient access in complex regulatory environments. We look forward to her expertise and invaluable contributions as we pursue our mission to transform the lives of people living with opioid use disorder."
"I am honored to join Indivior at this transformative time for the Company," said Ms. Procter. "Public policy and community engagement are critical to address this significant public health challenge; providing the framework, funding and systems necessary to ensure treatment in the right place and at the right time. I look forward to working with the Indivior team and deepening our engagement with the people and communities we serve to further this important work."
Ms. Procter brings 25 years of experience in the biopharmaceutical industry, having led corporate and government affairs for multiple organizations. Most recently, Ms. Procter was Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led a team that conditioned the environment for the successful product launch of ZURZUVAE鈩�, the first pill for post-partum depression. In that role, she led corporate communications, investor relations, government affairs and patient advocacy. Prior to her time at Sage, she was Head of
Ms. Procter earned her B.A. in History from Gettysburg College.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
听
View original content to download multimedia:
SOURCE Indivior PLC